Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Novartis |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00413270 |
This study will evaluate the safety of nilotinib in adult patients with imatinib-resistant or -intolerant CML-blast crisis, CML-accelerated phase or CML-chronic phase when treated with nilotinib. Patients will be provided access to nilotinib until the drug is available on the market.
Condition | Intervention | Phase |
---|---|---|
Chronic Myelogenous Leukemia |
Drug: nilotinib |
Phase III |
Study Type: | Expanded Access |
Official Title: | A Canadian Open-Label, Multicenter, Expanded Access Study of Oral Nilotinib in Adult Patients With Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase, or Chronic Phase |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Study ID Numbers: | CAMN107ACA01 |
Study First Received: | December 18, 2006 |
Last Updated: | May 1, 2008 |
ClinicalTrials.gov Identifier: | NCT00413270 History of Changes |
Health Authority: | Canada: Health Canada |
Imatinib resistant Imatinib intolerant CML- blast crisis CML- Accelerated phase |
CML- chronic phase nilotinib Imatinib resistant or- intolerant Chronic myelogenous leukemia in blast crisis, accelerated phase or chronic phase |
Imatinib Blast Crisis Leukemia Hematologic Diseases Myeloproliferative Disorders |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Chronic Myelogenous Leukemia Leukemia, Myeloid Bone Marrow Diseases Protein Kinase Inhibitors |
Blast Crisis Neoplasms by Histologic Type Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Hematologic Diseases Myeloproliferative Disorders Enzyme Inhibitors Leukemia, Myeloid Protein Kinase Inhibitors Pharmacologic Actions |
Imatinib Leukemia Neoplasms Neoplastic Processes Pathologic Processes Therapeutic Uses Leukemia, Myelogenous, Chronic, BCR-ABL Positive Bone Marrow Diseases Cell Transformation, Neoplastic |